Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings

SUZHOU, China and SAN FRANCISCO: Purchase of Assets and Related Global Commercialization Rights for Oral 9-cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness. Clinical Stage Asset Has Potential for First Approved Oral Therapy for Leber's Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP) Caused by Mutations of the RPE65 or Lecithin:Retinol...

Click to view original post